REG - MicroSalt PLC - Subscription to raise £1.5 million

MicroSaltAnnouncement

Tue 14:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8820Ka&default-theme=true

RNS Number : 8820K  MicroSalt PLC  09 December 2025

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as imported into the laws of England and Wales by virtue of
the European Union (Withdrawal) Act 2018 (as amended) and certain other
enacting measures ("UK MAR"). With the publication of this announcement via a
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

9 December 2025

MicroSalt Plc

("MicroSalt" or the "Company")

Subscription to raise £1.5 million

 

MicroSalt plc (AIM:SALT), a leading provider of full-flavour, natural salt
with approximately 50% less sodium, is pleased to announce it has closed a
fundraising of £1.5 million (c.US$2.0 million) through a subscription for
3,333,334 new ordinary shares of £0.001625 each in the Company ("Subscription
Shares") at a price of £0.45 per Subscription Share (the "Subscription" or
"Fundraising").

Key Highlights:

-       £1.5 million (US$2.0 million) before expenses was raised
pursuant to the Subscription through participants of the Fundraising
("Subscribers"), at a price of £0.45 per Subscription Share (the "Issue
Price"). The Issue Price represents a discount of approximately 13.5% to the
Company's last closing share price

-       Funds raised will be utilised as follows:

o  £1.0 million to increase production to support expected orders from
leading snack manufacturers;

o  £0.2 million for staffing, including a sales executive focused on
international Quick Service Restaurants ("QSR") and Fast Service Restaurants
("FSR") as well as further sales and finance support;

o  £0.1 million for marketing to assist MicroSalt with visibility in
industry publications, ingredient based sales events as well as to support
other marketing initiatives;

o  £0.1 million for general working capital purposes; and

o  £0.1 million for R&D efforts associated with new product development.

 

MicroSalt continues to deliver positive trading, with unaudited sales of $1.95
million for the eleven months to 30 November 2025 and therefore will exceed
its full-year revenue target of $2.0 million. The volume year to date
represents up to 754,298,168 servings of food have been made healthier by the
inclusion of Microsalt. The Company has strengthened its relationship with a
major global food manufacturer through a proposed four-year Joint Development
Agreement and initiated recurring bulk orders. These developments support
MicroSalt's growth plans, with projected revenues of in hand volume
requirements totalling $7.0 million in 2026 and over $15.0 million in 2027.

The net proceeds of the Subscription will substantially strengthen the
Company's balance sheet and, based on management forecasts, are expected to be
sufficient to fund the business for the next 12 months.

Retail Offer

In addition to the Subscription, the Company intends to provide all existing
shareholders with the opportunity to subscribe for an aggregate of up to
666,666 Ordinary Shares at the Issue Price (the "Retail Offer Shares"), via
the Bookbuild Platform ("Bookbuild"), to raise up to approximately £0.3
million (before expenses) (the "Retail Offer").

A further announcement will be made in due course regarding the Retail Offer,
detailing its terms. It is expected that the Retail Offer will launch later
today and will close at 12:00 p.m. on 12 December 2025.

 

Details of the participation in the Subscription by Directors

Pursuant to the Subscription, the following Directors have agreed to subscribe
for Subscription Shares as set out in the table below:

 Subscriber        Role                    Subscription Shares subscribed for  Ordinary Shares after Subscription
 Judith Batchelar  Chair                   22,222                              115,246
 Dan Emery         Non-Executive Director  22,222                              22,222
 Gary Urmston      Interim CFO             22,222                              115,246

 

 

Rick Guiney, CEO of MicroSalt, commented:

"2025 has been a year of strong, sustained growth across the business as we
expand our presence within the fast-growing low sodium market. Our rising
order book, advanced technical capabilities in regard to low sodium
applications and product offerings continue to validate our strategy. As
global sodium reduction legislation accelerates, MicroSalt is well positioned
to capitalise on this growing opportunity and build a solid, long-term
customer base.

By the end of November 2025, we have delivered 752,289,168 healthier servings
of food, over three-quarters of a billion servings, a significant milestone
that underscores the reach of our impact. This is complimented by our sales
through November reaching $1.9M, with record revenues of $295,000 in November
alone, which provides us with confidence and security in exceeding our
previous annual guidance of $2m.

We are delighted to see continued support from our existing shareholders, and
welcome new shareholders onto our register. This fundraise will enable us to
solidify larger production schedules in 2026 to execute our in-hand and
anticipated volumes from customers and bring us one step closer to being
profitable and cash generative."

Subscription Shares Admission

The Subscription Shares will, when issued, rank pari passu in all respects
with the existing Ordinary Shares then in issue. Application has been made for
the 3,333,334 Subscription Shares to be admitted to trading on AIM and
dealings are expected to commence at 8.00 a.m. on 15 December 2025.

For more information, please visit MicroSalt's website
(https://microsaltinc.com/home-uk/) , follow on Twitter @MicroSaltPLC
(https://twitter.com/MicroSaltPLC)  or contact:

 

Enquiries:

 

 MicroSalt plc                                    info@microsaltinc.com
 Rick Guiney (CEO)

 Zeus (Nominated Adviser and Broker)              +44 (0)20 3829 5000
 David Foreman / James Edis (Investment Banking)

 Gracechurch Group (Financial PR)                 +44 (0)20 4582 3500
 Heather Armstrong, Alexis Gore, Rebecca Scott

 

 

About MicroSalt

MicroSalt® is disrupting the global salt market with its patented,
full-flavour, low-sodium salt designed for both food manufacturers and
consumers. Using proprietary micron-sized particles, MicroSalt® delivers the
same salty taste as traditional salt with approximately 50% less sodium,
offering a scalable solution to one of the world's most pressing health
challenges. Year to date through 2025, MicroSalt® has contributed to more
than 634M servings made healthier.

Excess sodium consumption is a leading contributor to cardiovascular disease,
the world's number one cause of death. The World Health Organisation has
targeted a 30% reduction in global sodium intake by 2025, a shift projected to
save seven million lives by 2030. The economic case is equally compelling: in
the UK alone, cardiovascular disease costs £19 billion annually, and reducing
average daily salt intake by just one gram could save over 4,000 lives and
£288 million each year.

Operational since 2018, MicroSalt® has established a defensible IP portfolio,
holding a granted US patent and 14 pending applications worldwide. These
protections create significant barriers to entry in a market expected to grow
exponentially as regulation and consumer demand accelerate.

MicroSalt® is ideally positioned for scale and market leadership, with clear
pathways into food manufacturing, consumer channels, and ultimately the
broader £10+ billion global salt market. MicroSalt® is more than a healthier
alternative-it is a disruptive, category-defining solution poised to deliver
significant commercial and societal impact.

For more information, please visit www.microsaltinc.co
(http://www.microsaltinc.co) or follow on X @microSaltPLC.

IMPORTANT INFORMATION

 

The information contained in this announcement ("Announcement") does not
constitute an offering of securities for sale in the United States of America
and no securities have been or will be registered under the United States
Securities Act 1933, as amended (the "Securities Act") or under the securities
laws of any state or other jurisdiction in the United States of America nor
will they qualify for distribution under any of the relevant securities laws
of Australia, Canada, Japan or the Republic of South Africa. The securities
may not be offered or sold in the United States of America. This Announcement
is not for distribution directly or indirectly in or into the United States of
America, Australia, Canada, Japan or the Republic of South Africa or in any
other jurisdiction in which such publication or distribution is unlawful.

 

This Announcement does not constitute a prospectus or prospectus equivalent
document for the purposes of the prospectus rules and has not been, and will
not be, approved by, or filed with, the Financial Conduct Authority ("FCA").
It does not constitute or form part of, and should not be construed as, an
offer to sell or issue, or a solicitation of any offer of or invitation to buy
or subscribe for, any securities, nor shall it (or any part of it), or the
fact of its distribution, form the basis of, or be relied on in connection
with, or act as an inducement to enter into, any contract or commitment
whatsoever. Any failure to comply with these restrictions may constitute a
violation of the applicable securities laws in such jurisdiction. This
Announcement does not constitute a recommendation regarding any securities.

 

This Announcement contains (or may contain) certain forward-looking statements
with respect to certain of the Company's plans and its current goals and
expectations relating to its future financial condition and performance, which
involve a number of risks and uncertainties. The Company cautions readers that
no forward-looking statement is a guarantee of future performance and that
actual results could differ materially from those contained in the
forward-looking statements. These forward-looking statements can be identified
by the fact that they do not relate only to historical or current facts.
Forward-looking statements sometimes use words such as "aim", "anticipate",
"target", "expect", "estimate", "intend", "plan", "goal", "believe", or other
words of similar meaning. By their nature, forward-looking statements involve
risk and uncertainty because they relate to future events and circumstances,
including, but not limited to, economic and business conditions, the effects
of continued volatility in credit markets, market-related risks such as
changes in the price of commodities or changes in interest rates and foreign
exchange rates, the policies and actions of governmental and regulatory
authorities, changes in legislation, the further development of standards and
interpretations under International Financial Reporting Standards (IFRS)
applicable to past, current and future periods, evolving practices with regard
to the interpretation and application of standards under IFRS, the outcome of
pending and future litigation or regulatory investigations, the success of
future explorations, acquisitions and other strategic transactions and the
impact of competition. A number of these factors are beyond the Company's
control. As a result, the Company's actual future results may differ
materially from the plans, goals, and expectations set forth in the Company's
forward-looking statements. Any forward-looking statements made in this
Announcement by or on behalf of the Company speak only as of the date they are
made. Except as required by the FCA, the London Stock Exchange plc or
applicable law, the Company expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements
contained in this Announcement to reflect any changes in the Company's
expectations with regard thereto or any changes in events, conditions or
circumstances on which any such statement is based.

 

This Announcement is for information purposes only and shall not constitute an
offer to buy, sell, issue, or subscribe for, or the solicitation of an offer
to buy, sell, issue, or subscribe for any securities, nor shall there be any
sale of securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification, or exemption,
under the securities laws of any such jurisdiction.

 

This Announcement has been issued by and is the sole responsibility of the
Company. No representation or warranty, express or implied, is or will be made
as to, or in relation to, and no responsibility or liability is or will be
accepted by Zeus Capital Limited ("Zeus") or by any of their affiliates or
agents as to, or in relation to, the accuracy or completeness of this
Announcement or any other written or oral information made available to or
publicly available to any interested party or its advisers, and any liability
therefore is expressly disclaimed.

 

Zeus is authorised and regulated by the FCA. Zeus is acting for the Company
and for no-one else in connection with the Subscription, and will not be
responsible to anyone other than the Company for providing the protections
afforded to its customers or for providing advice to any other person in
relation to the Subscription or any other matter referred to herein.

 

 

The distribution of this Announcement and the offering of the Subscription
Shares in certain jurisdictions may be restricted by law. No action has been
taken by the Company or Zeus that would permit an offering of such shares or
possession or distribution of this Announcement or any other offering or
publicity material relating to such shares in any jurisdiction where action
for that purpose is required. Persons into whose possession this Announcement
comes are required by the Company or Zeus to inform themselves about, and to
observe such restrictions.

 

Persons (including, without limitation, nominees and trustees) who have a
contractual or other legal obligation to forward a copy of the Appendix or
this Announcement should seek appropriate advice before taking any action.

 

The Subscription Shares to which this Announcement relates may be illiquid
and/or subject to restrictions on their resale. Prospective purchasers of the
Subscription Shares should conduct their own due diligence on the Subscription
Shares. If you do not understand the contents of this Announcement you should
consult an authorised financial adviser.

 

Neither the content of the Company's website nor any website accessible by
hyperlinks on the Company's website is incorporated in, or forms part of, this
Announcement.

 

All times and dates in this Announcement may be subject to amendment. The
Company and Zeus shall notify the Subscribers and any person acting on behalf
of the Subscribers of any changes.

 

Each distributor is responsible for undertaking its own target market
assessment in respect of the Subscription Shares and determining appropriate
distribution channels.

 

Solely for the purposes of the product governance requirements contained
within the following, each as imported into the laws of England and Wales by
virtue of the European Union (Withdrawal) Act 2018 (as amended) and certain
other enacting measures: (a) EU Directive 2014/65/EU on markets in financial
instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission
Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local
implementing measures (together, the "MiFID II Product Governance
Requirements"), and disclaiming all and any liability, whether arising in
tort, contract or otherwise, which any "manufacturer" (for the purposes of the
Product Governance Requirements) may otherwise have with respect thereto, the
Subscription Shares have been subject to a product approval process, which has
determined that the Subscription Shares are: (i) compatible with an end target
market of: (a) retail investors; (b) investors who meet the criteria of
professional clients; and (c) eligible counterparties, each as defined in
MiFID II; and (ii) eligible for distribution through all distribution channels
as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding
the Target Market Assessment, Distributors should note that the price of the
Subscription Shares may decline and investors could lose all or part of their
investment; the Subscription Shares offer no guaranteed income and no capital
protection; and an investment in the Subscription Shares is compatible only
with investors who do not need a guaranteed income or capital protection, who
(either alone or in conjunction with an appropriate financial or other
adviser) are capable of evaluating the merits and risks of such an investment
and who have sufficient resources to be able to bear any losses that may
result therefrom. The Target Market Assessment is without prejudice to the
requirements of any contractual, legal or regulatory selling restrictions in
relation to an offer of securities such as the Subscription Shares.

 

For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest
in, or purchase, or take any other action whatsoever with respect to the
Subscription Shares.

 

Each distributor is responsible for undertaking its own target market
assessment in respect of the Subscription Shares and determining appropriate
distribution channels.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFZMGZDLVGKZM



            Copyright 2019 Regulatory News Service, all rights reserved